Patient monitor system developer EarlySense announced today that its EverOn Central Display Station (CDS) has been cleared for marketing by the US Food and Drug Administration (FDA).
The FDA clearance covers the ability of the system to collect real time vital sign information from up to 36 EverOn bedside monitors and display the information on a computer screen at the nurse’s station.
The EverOn system now also sends relevant alerts to the mobile phones of the nurses, enabling real time notification of any adverse changes in a patient’s vital signs.
EarlySense CEO Avner Halperin said that the FDA nod lets the company offer a solution that enables proactive patient care. Halperin said, "With today’s increased focus on improved quality and patient safety targets coupled with the challenges of shrinking budgets, hospitals are turning to advanced technologies such as EverOn to provide effective alerts on high risk situations."
The data is collected by the EverOn system’s contact-free sensor placed under the hospital bed mattress. It has no leads or cuffs and never touches the patient.
The data collected by the EverOn system is also replicated on large LCD displays on the medical surgical floors enabling the clinical teams, as they move from room to room, to continuously and actively observe the condition status of patients and any corresponding patient safety alerts.
EarlySense is based in Ramat Gan.
The newly cleared CDS augments the EverOn contact-free, patient supervision system approved in June 2010.
Published by Globes [online], Israel business news - www.globes-online.com - on October 4, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010